Why are you looking at Genovac Antibody Discovery?
Capability
Service linesRESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY (EXCEPT NANOBIOTECHNOLOGY)
Work mix: 100% prime · 0% sub · primary NAICS 541714 / PSC B537 SPECIAL STUDIES/ANALYSIS- MEDICAL/HEALTH
Where they win
Sole agencyMostly sole-source · 99%
99% of Genovac Antibody Discovery’s obligations are not openly competed — these contracts typically renew with the incumbent rather than going to recompete.
Agency buyer map
1 buyersRecompete exposure
LowLargely sole-source — these contracts typically renew with Genovac Antibody Discovery rather than being openly recompeted.
Genovac Antibody Discovery has an estimated $120K in contracts returning to market over the next 24 months. 1 within 6 months.
GET THE FULL BRIEF
Get Genovac Antibody Discovery’s recompete exposure, top agencies and teaming history
The outlook above is free to read and verify — an estimated $121K in play. Enter a work email for two figures the page cannot show.
“SCOUT saves the hours of analysis that capture and proposal teams cannot afford to lose by delivering analyzed intelligence. Incumbent history, competitive positioning, and agency buying patterns get synthesized into…”
Enter your company name and we'll build the page.
Query this company live in SCOUT via MCP — personalized displacement scoring, alerts, and capture workflow. Learn about SCOUT MCP →
Frequently asked questions
What federal contracts does Genovac Antibody Discovery hold?
Genovac Antibody Discovery (UEI XLZUCKG5TEJ5) shows $121K across 2 award actions in SCOUT’s public USASpending-backed profile, with Department of Defense (DOD) as the top buying agency. Totals cover federal prime awards ≥$100K in the rolling window.
Which agencies does Genovac Antibody Discovery work with?
Genovac Antibody Discovery’s firm-wide obligated mix is led by Department of Defense (DOD) (100%).
Does Genovac Antibody Discovery have contracts coming up for recompete?
Yes — SCOUT tracks 1 incumbent recompete in the next 24 months (Low exposure). Open the recompete section on this page for PIID-level timing.
SCOUT Signal
August 2026
One VA health contract was 35% of civilian federal obligations in July.
Meanwhile VA's service-disabled veteran-owned contract actions fell 41.8%. The same agency, the same month, the large-vendor lane expanding while the small-business lane contracted. Figures are civilian-agency obligations through 2026-07-31; DoD FPDS for this window is labeled incomplete.
This issue is the whole civilian market. Your capture plan isn't.
Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows. Explore it live — $90 Pilot →